Back to News & Media
Tuesday, July 25, 2017

Draper Uses the Body's Self Defense to Find Cancer Therapies

Finding the right cancer therapy using a novel approach: dynamic microenvironments

CAMBRIDGE, MA – Cancer causes one of every four deaths in the United States and bears a direct cost to our health care system of close to $100B annually. Over the past several decades, therapeutic approaches toward cancer have developed around surgery, radiation and chemotherapy. And yet, a key challenge remains for biomedical researchers:  how to develop tools that accurately predict treatment efficacy against a patient’s specific cancer, thereby avoiding subjecting the patient to a potentially life-threatening trial-and-error process to find the best drug. 

Draper engineers, who have developed technologies to treat failure of the liver, kidney, lung and other organs, created a microfluidic system that brings the individual patient into the therapeutic compound discovery process for cancer therapies. By marshaling a patient’s immune system to destroy their cancer—a method known as immuno-oncology—clinicians using Draper’s device can refine and accelerate cancer treatments in ways that extend well beyond the conventional laboratory system, all by tapping into a patient’s own biology. 

A key feature of Draper’s platform, called the Personalized Predictive Assay for Cancer Treatment (PPACT), is its ability to recapitulate the interaction between a patient’s immune cells and their tumor. 

With PPACT, biomedical researchers can create a microenvironment—a test bed of sorts—complete with an engineered vascular-like system containing nutrients and lymphocytes, providing suitable conditions to sustain a 3D fragment of the patient’s biopsied tumor tissue. A precision-controlled microfluidic system delivers various drugs or combinations of drugs along with lymphocytes treated with various compounds, to determine which are most effective at killing the patient’s cancer. The current prototype is a 12-channel device to support parallel testing of multiple tumor fragments and combinations of drugs. If a drug is observed to kill tissues within the PPACT platform, it provides predictive evidence of clinical efficacy against the patient’s cancer.

Draper’s microfluidics PPACT system fits into the growing field of personalized therapeutics and precision medicine, according to Jeff Borenstein, Laboratory Technical Staff at Draper. In tests, Borenstein and his team found that the PPACT system could recapitulate responses seen in studies with mouse models, but within a framework that permits precision control over the tumor microenvironment and real-time monitoring of immune cell function and tumor response. 

“The precision and scalability of the microfluidic design enables testing of a large number of therapeutic combinations simultaneously within time frames as short as one week so that patients can start with the right treatment, right away,” Borenstein said.

Because PPACT incorporates circulating immune cells from individual patients in the microfluidic system, it can test the effectiveness of immunotherapy drugs, which unleash the body’s own immune system to fight cancer. Many tumors have developed the ability to locally shut off components of a patient’s immune system, thereby enabling the tumor to grow and thrive unimpeded. With the right immune checkpoint inhibitor, the ability to block the immune response is turned off, and the patient’s T-cells are able to attack the cancer. When immune checkpoint inhibitors work, they are remarkably successful, producing long remissions, as experienced by Jimmy Carter in 2015. There are currently more than 20 immune checkpoint inhibitor drugs on the market, but not every cancer responds to each one, and conventional tools to predict the best one are inadequate.

For companies in need of more-effective cell therapy processing solutions and drug selection options, Draper’s extensive experience and expertise in biology, microfluidics, system integration and subsystem maturity can be applied to designing closed systems; automated, standardized processes; end-to-end solutions; continuous processing; and scalable solutions. These improvements to processes and technologies can help pharmaceutical companies solve the engineering challenges of production to achieve the cost reductions, accelerated results, reduced risk and increased safety that they need to make precision medicine practical.

By marshaling a patient’s immune system to destroy their cancer—a method known as immuno-oncology—Draper's PPACT device is helping test the effectiveness of immunotherapy drugs. Immune cells (green and red) prepare to destroy a cancer cell (blue, center)
Capabilities Used

Draper has designed and developed microelectronic components and systems going back to the mid-1980s. Our integrated, ultra-high density (iUHD) modules of heterogeneous components feature system functionality in the smallest form factor possible through integration of commercial-off-the-shelf (COTS) technology with Draper-developed custom packaging and interconnect technology. Draper continues to pioneer custom Microelectromechanical Systems (MEMS), Application-Specific Integrated Circuits (ASICs) and custom radio frequency components for both commercial (microfluidic platforms organ assist, drug development, etc.) and government (miniaturized data collection, new sensors, Micro-sats, etc.) applications.  Draper features a complete in-house iUHD and MEMS fabrication capability and has existing relationships with many other MEMS and microelectronics fabrication facilities. 

Biomedical Solutions

Draper’s Biomedical Solutions capability centers on the application of microsystems, miniaturized electronics, computational modeling, algorithm development and image and data analytics applied to a range of challenges in healthcare and related fields. Draper fills that critical engineering niche that is required to take research or critical requirements and prototype or manufacture realizable solutions.  Some specific examples are MEMS, microfluidics and nanostructuring applied to the development of wearable and implantable medical devices, organ-assist devices and drug-delivery systems. Novel neural interfaces for prosthetics and for treatment of neurological conditions are being realized through a combination of integrated miniaturized electronics and microfabrication technologies.

Materials Engineering & Microfabrication

Draper continues to develop its expertise in designing, characterizing and processing materials at the macro-, micro- and nanoscales. Understanding the physical properties and behaviors of materials at these various scales is vital to exploit them successfully in designing components or systems. This enables the development and integration of biomaterials, 3D printing and additive manufacturing, wafer fabrication, chemical and electrochemical materials and structural materials for application to system-level solutions required of government and commercial sponsors.

Media Contact

Media Relations

Contact Info: 
Strategic Communication

Media Relations